Previous studies have shown that owl monkeys which have had a trachoma agent infection were subsequently highly resistant to challenge by both homologous and heterologous organisms. In the present study, passive transfer of owl monkey serum containing antitrachoma antibody from immune monkeys did not protect recipient monkeys from infectious challenge with homologous trachoma. Antibody was not detectable in eye secretions of the recipient monkeys until the intensity of infectioil was waning, suggesting but not proving that local antibody synthesis rather than simple transudation of serum antibody occurs.
The owl monkey (Aotus trivirgatus) has been used as an animal model for trachoma agent infection in man (1) . The chronicity characteristic of the disease process in man is lacking, but the acute infection is similar and warrants study because of its potential for insight into the human disease. Experimentally induced trachoma in the owl monkey thus produces acute purulent conjunctivitis with numerous inclusions in conjunctival epithelial cells. These symptoms and signs are observed consistenitly when monkeys are infected with at least 20 mean egg infectious doses (EID50) of trachoma agent (1, 6) .
In a previous study when owl monkeys were challenged 70 days after a primary trachoma infection, inclusion rates were 25-to 200-fold lower after infectious challenge than after the initial infection (6) . The present experiments investigated the nature of this resistance to reinfection by determining whether passive transfer of serum antibody would protect recipient monkeys against challenge by a minimal infective dose of trachoma.
MATERIALS AND METHODS Owl monkeys. Owl monkeys (A. trivirgatus) were obtained from a commercial importer by the New England Regional Primate Research Center. Prior to this study, all monkeys were free from clinical signs of trachoma infection and were negative for serum and eye secretion antibodies to HAR-13, HAR-32, and HAR-36 trachoma antigens (representing all three serotypes of ocular trachoma) as measured by indirect immunofluorescence. In addition, there was no evidence of trachoma inclusions in their conjunctival epithelial cells as judged by immunofluorescent staining (8) .
Trachoma. Trachoma agent strain TRIC/l/ ET/HAR-13/OT (HAR-i3) was tsed both to infect the serum donor monkeys and to challenge the serum recipient monkeys. The trachoma organism was maintained, cultivated, and titered in chicken embryo yolk sacs as previously described (4, 6 After 14 days, these animals were again given identical doses of the infectious organism. Ten days after this second dose of trachoma agent, the monkeys were killed, and their sera were aseptically collected and stored at 4 C.
With one exception, these monkeys appeared totally resistant to reinfection; conjunctival cells of these monkeys (on days 0, 14, 21, and 24) did not contain any inclusions in over 66,000 cells examined. One monkey (Dl), however, had an inclusion rate of 0.4 (4 inclusions in 10,000 cells) on a single day: the day its serum was collected (day 24). These data were interpreted as consistent with strong resistance to infection.
Two control donor monkeys (D3 and D4) without previous exposure to trachoma agent were treated identically except that they received the same amount of uninfected yolk sac instead of yolk sac-grown trachoma.
Antibody determinations. Fourfold dilutions of serum and eye secretions were tested for antibody to HAR-13 slide antigen as previously described (8) .
Serum transfer. Three recipient test monkeys (R1, R2, and R3) each received intraperitoneally 9.0 ml of serum containing antitrachoma antibodies. The antibody-containing serum from each of the two donor monkeys (Dl and D2) had an immunofluorescence titer of 1:10,240. Two control monkeys (R4 and R5) each received 9.0 ml of antibody-negative serum, and one control monkey (R6) received no serum (Table 1) .
Infectious ocular challenge of serumrecipient monkeys. Three days after serum transfer, test and control monkeys were challenged by the inoculating into each eye 20 EIDw of trachoma organisms contained in 20 Mliters of a 1:1,'000 dilution of crude yolk sac. In our experience this is the lowest dose which will insure infection of all monkeys challenged (6).
Microbiological measurement of infection.
Intensity of infection was quantitated by inclusion rates (inclusions per 1,000 conj unctival epithelial cells). Conj unctival cells were taken from the tarsal plate of the everted upper eyelid with a blunt dental scraper and transferred to a microscope slide. The smear was allowed to air-dry and was then acetone-fixed for 10 min. Slides were stored at -20 C and subsequently stained with (3) . Samples from the right and left eyes of a given monkey were pooled by dropping both sponges into 0.4 ml of phosphate-buffered saline (0.15 M sodium phosphate, 0.85% sodium chloride, pH 7.2) for an initial dilution of approximately 1:5.
General procedures. Each monkey was sedated with 0.05 ml of phencyclidine hydrochloride (Sernylan, Parke Davis and Company, Detroit, Mich.). The presence and severity of ocular discharge was determined by gross clinical examination. After eversion of the eyelid, the degree of hyperemia was recorded. Eye secretions were taken, and blood was then drawn. When performed, serum transfer and infectious challenge were the last procedures to be done on that particular day.
RESULTS
Antibody in recipient monkeys. The serum and eye secretion antibody titers are shown in Tables 2 and 3 , respectively. The three monkeys which received passively transferred serum had levels of circulatory antitrachoma antibody at day zero (3 days after receipt of donor sera, Table 2 ) which were similar to levels which previously have been correlated with resistance to challenge (3) . No antibody was detectable in the eye secretions of these recipient test monkeys after serum transfer until day 28 (Table 3) .
Microbiological evidence of trachoma infection. The rate of inclusions was calculated on the basis of total inclusions in both eyes (Table 4 ). All monkeys became infected after the trachoma challenge. An analysis of variance did not indicate anly significant differences at the 95% confidence level between the severity of infection in control and antibody recipient groups. The circulating antitrachoma antibody passively transferred to the test group of monkeys did not protect against homologous challenge (Table 4) .
DISCUSSION
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The fact that passively transferred antitrachoma antibody did not protect against challenge is consistent with the analogous findings in similar studies in the guinea pig by Watson et al. (9) . Passively transferred serum antibody in our study neither delayed nor attenuated ocular infection. By contrast, none of the previously infected control animals was susceptible to reinfection although many 
